AFP and hepatocellular carcinoma: There have only been two randomized controlled trials to examine the issue of HCC screening in patients with CHB: the first—a methodologically flawed study performed in Shanghai, China—showed a mortality benefit of biannual ultrasound screening [35], while a study examining the use of AFP in Qidong, China showed no mortality benefit [36].